Shattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8
Shattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8
Shattuck Labs (NASDAQ: STTK) will host an investor call and webcast on June 8, 2026 at 8:00 a.m. ET to present comprehensive Phase 1 clinical data for SL-325, a potentially first-in-class DR3 blocking antibody, and provide a pipeline update.
The event will feature Shattuck’s management team and include a Q&A session, with live and replay access via the company’s website.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – STTK
-14.85%
5 alerts
-14.85%Session close to close
+4.8%Peak in 8 hr 33 min
$368.07MMarket Cap
0.1xRel. Volume
In the Jun 8 session, STTK declined 14.85%, reflecting a significant negative market reaction.
Argus tracked a peak move of +4.8% during that session.
Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility.
The stock dropped -14.8% in the session following this news. A negative reaction despite an upcoming...
Analysis
The stock dropped -14.8% in the session following this news. A negative reaction despite an upcoming data call would fit prior modest weakness of -1.76% around similar conference/clinical communications. Investors may reassess risk ahead of detailed SL-325 Phase 1 results and potential future trials. The existing $200,000,000 shelf capacity also frames expectations for how additional capital raises tied to development plans could affect the share balance.
Key Figures
Event date:June 8, 2026Event time:8:00 a.m. ETWebcast replay window:30 days
3 metrics
Event dateJune 8, 2026Investor call and webcast on SL-325 Phase 1 data
Event time8:00 a.m. ETScheduled start time for SL-325 Phase 1 data call
Webcast replay window30 daysReplay availability after the SL-325 data webcast
Announced investor call on additional interim Phase 1B SL-172154 data at EHA 2024.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent Company History
Recent history shows Shattuck steadily advancing its pipeline while engaging investors around key data. Prior tagged conference/clinical news in June 2024 involved an investor call on additional Phase 1B data for SL-172154 during the EHA 2024 Congress, with a modest -1.76% price reaction. Separately, earnings updates in Q4 2025 and Q1 2026 highlighted completion of SL-325 Phase 1 enrollment and plans for a Phase 2 Crohn’s trial, framing today’s SL-325 Phase 1 data call as part of a planned clinical progression.
Key Terms
phase 1 clinical data, pharmacokinetics, receptor occupancy, pharmacodynamic, +4 more
8 terms
phase 1 clinical datamedical
"to present comprehensive Phase 1 clinical data for SL-325, including safety..."
Phase 1 clinical data are the earliest results from first-in-human tests that assess whether a new drug or medical treatment is safe, how the body processes it, and what dose people can tolerate. For investors, these data are an early safety and feasibility check — like crash‑testing a car prototype — that helps gauge scientific risk, potential development costs and the likelihood the program will advance to larger, value-driving trials.
Pharmacokinetics is the study of how a substance, such as a drug or chemical, moves through and is processed by the body over time. It tracks how it is absorbed, distributed, broken down, and eventually eliminated. For investors, understanding pharmacokinetics helps gauge the effectiveness, safety, and potential risks of new medications or treatments, which can influence a company’s success and valuation in the healthcare industry.
receptor occupancymedical
"tolerability, pharmacokinetics, receptor occupancy, pharmacodynamic and immunogenicity..."
Receptor occupancy is the share of a target protein on cells that a drug is actually bound to at a given dose, often expressed as a percentage. Think of receptors as parking spaces and the drug as cars: higher occupancy means more spaces are filled, which helps predict how well the drug will work and how likely it is to cause side effects. Investors watch this measure because it links dose and clinical effects to regulatory success and commercial potential.
pharmacodynamicmedical
"receptor occupancy, pharmacodynamic and immunogenicity results and provide a pipeline update."
Pharmacodynamic describes how a drug acts on the body — the biological effects it produces, how strong those effects are, and how long they last. For investors, pharmacodynamic data show whether a treatment actually works and at what dose, shaping expectations about a drug’s safety, effectiveness, regulatory success and market potential; think of it like testing how well a key turns a lock and whether it reliably opens the door.
immunogenicitymedical
"receptor occupancy, pharmacodynamic and immunogenicity results and provide a pipeline update."
Immunogenicity is the ability of a substance, such as a vaccine or medication, to provoke an immune response in the body. It matters to investors because high immunogenicity can affect the effectiveness and safety of a product, potentially leading to increased costs or regulatory challenges. Understanding immunogenicity helps assess the long-term viability and market potential of pharmaceutical and biotech investments.
webcasttechnical
"announced that it will host an investor call and webcast on Monday, June 8, 2026..."
A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.
monoclonalmedical
"first-in-class monoclonal and bispecific DR3-blocking antibodies for the treatment..."
Monoclonal describes a therapeutic product or laboratory reagent made from a single original cell, so every molecule or antibody in the batch is virtually identical. Investors care because that uniformity usually means predictable behavior, easier quality control, clearer regulatory approval paths and stronger intellectual property; think of it like manufacturing identical keys rather than cutting many different ones by hand, which reduces surprises and supports reliable production and pricing.
bispecificmedical
"first-in-class monoclonal and bispecific DR3-blocking antibodies for the treatment..."
A bispecific molecule is a therapeutic designed to bind two different biological targets at once — imagine a two-headed key that fits two locks simultaneously. For investors, bispecific therapies matter because that dual-action can make a treatment more effective or selective, potentially improving clinical results, altering safety profiles, and creating a stronger commercial edge; those factors directly affect development risk, regulatory chances, and future revenue prospects.
AUSTIN, Texas and DURHAM, N.C., June 05, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3-blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced that it will host an investor call and webcast on Monday, June 8, 2026 at 8:00 a.m. ET to present comprehensive Phase 1 clinical data for SL-325, including safety, tolerability, pharmacokinetics, receptor occupancy, pharmacodynamic and immunogenicity results and provide a pipeline update.
The event will feature presentations by members of Shattuck’s management team, including Taylor Schreiber, M.D., Ph.D., Chief Executive Officer, Lini Pandite, M.D., M.B.A., Chief Medical Officer, Suresh De Silva, Ph.D., Chief Scientific Officer, Michael Choi, M.D., Vice President of Clinical Development, and Andrew Neill, M.B.A., Chief Financial Officer, followed by a question-and-answer session.
Conference Details
Title: Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update Date & Time: Monday, June 8, 2026 at 8:00 a.m. ET Webcast Details:Click here
Interested parties can access the live webcast via the Events & Presentations section of the Company’s website at www.shattucklabs.com. A replay of the webcast will be available for approximately 30 days following the event.
About SL-325 SL-325 is a potential first-in-class Death Receptor 3 (DR3) blocking antibody designed to achieve a complete and durable blockade of the clinically validated DR3/TL1A pathway. Shattuck’s preclinical studies demonstrate high affinity binding and superior activity over TL1A antibodies, and offer a data-driven rationale for targeting the TNF receptor, DR3, versus its ligand, TL1A. SL-325 is a fully Fc-silenced, fully human immunoglobulin G monoclonal antibody with a favorable safety profile in non-human primates, currently being evaluated in a Phase 1 clinical trial.
About Shattuck Labs, Inc. Shattuck Labs, Inc. is a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases. Shattuck’s expertise in protein engineering and the development of novel TNF receptor therapeutics come together in its lead program, SL-325, a potentially first-in-class DR3 antagonist antibody designed to achieve a more complete blockade of the clinically validated DR3/TL1A pathway. The Company has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.
Investor & Media Contact: Andrew R. Neill Chief Financial Officer Shattuck Labs, Inc. InvestorRelations@shattucklabs.com
FAQ
When is the Shattuck Labs (NASDAQ: STTK) SL-325 Phase 1 investor call on June 8, 2026?
The SL-325 Phase 1 investor call is scheduled for Monday, June 8, 2026 at 8:00 a.m. ET. According to Shattuck, the event will present Phase 1 clinical data and a broader pipeline update for investors.
How can investors access the Shattuck Labs (STTK) SL-325 Phase 1 webcast?
Investors can access the live SL-325 webcast through the Events & Presentations section of Shattuck’s website. According to Shattuck, a direct webcast link will be available there for participants interested in the data and pipeline update.
Will a replay of the Shattuck Labs (STTK) June 8, 2026 SL-325 webcast be available?
Yes, a replay of the June 8, 2026 SL-325 webcast will be available for about 30 days. According to Shattuck, the replay can be accessed via the Events & Presentations section of its corporate website after the live event.
What topics will Shattuck Labs (STTK) cover about SL-325 in the June 8, 2026 investor call?
The call will cover comprehensive Phase 1 data for SL-325, including safety and pharmacokinetics. According to Shattuck, topics also include tolerability, receptor occupancy, pharmacodynamic, immunogenicity results, and a broader pipeline update for inflammatory and immune-mediated disease programs.
Who from Shattuck Labs management will present on the June 8, 2026 SL-325 investor webcast?
Presenters include CEO Taylor Schreiber, CMO Lini Pandite, CSO Suresh De Silva, VP Clinical Development Michael Choi, and CFO Andrew Neill. According to Shattuck, management will lead presentations and participate in a question-and-answer session with investors.
